Work

VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology Group.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.3077

Authors: Bradley J. Monk, William E. Brady, Heather A. Lankes, Andrea Facciabene, Kristi Manjarrez, Robert Mark Hershberg, Paula M. Fracasso, Katherine M. Bell-McGuinn, Joan L. Walker, Carolyn K. McCourt, Carol Aghajanian, George Coukos

Institutions: Creighton University, St. Joseph's Hospital and Medical Center, Roswell Park Comprehensive Cancer Center, Gynecologic Oncology Group, University of Pennsylvania, University of Virginia, Memorial Sloan Kettering Cancer Center, University of Oklahoma Health Sciences Center, Women & Infants Hospital of Rhode Island

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2232866412

Cites:

Cited by: 5

Related to: 10